<DOC>
	<DOCNO>NCT02811822</DOCNO>
	<brief_summary>This study evaluate GMI-1271 , specific E-selectin antagonist , multiple myeloma adjunct standard care chemotherapy use treat disease .</brief_summary>
	<brief_title>A Study Determine Efficacy , Safety Pharmacokinetics GMI-1271 Adjunct Standard Care Treatment Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>1 . Males females â‰¥ 18 year age 2 . Confirmed diagnosis Multiple Myeloma 3 . Subjects progressive MM receive least 1 prior therapy already undergone expect undergo hematopoietic stem cell transplantation 4 . Subjects previously treat IMiDbased regimen ineligible IMiDbased treatment regimen 5 . Subjects must receive treatment proteasome inhibitorbased regimen ( bortezomibbased carfilzomibbased ) 6 . Adequate hepatic , renal , cardiac function 1 . Intolerant bortezomib carfilzomib 2 . Progressing evidence end organ damage attribute underlying disease 3 . Plasma cell leukemia 4 . Congestive heart failure 5 . Acute active infection 6 . Nonhematologic malignancy within past 3 year except : ) adequately treat basal cell squamous cell skin cancer , b ) carcinoma situ cervix , c ) prostate cancer stable PSA 7 . Significant peripheral neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>GMI-1271</keyword>
	<keyword>bortezomib</keyword>
	<keyword>carfilzomib</keyword>
	<keyword>multiple myeloma</keyword>
</DOC>